Fluciclovine PET/CT in Multiple Myeloma Patients

Myeloma, Multiple Clinical Trial

— FLUCIPET  

Official title:

PET i Diagnostikk og Behandlingsrespons av Pasienter Med Myelomatose

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03966443
• Other study ID #: 2018/2212/REK
• Status: Recruiting
• Start date: March 1, 2019
• Est. completion date: January 31, 2029

Study information

• Verified date: May 2019
• Source: Oslo University Hospital
• Contact: Mona-Elisabeth Revheim, MD, PhD, MHA
• Phone: +4790659373
• Email: monar[@]ous-hf.no
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: January 31, 2029
• Est. primary completion date: January 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Multiple myeloma patients suitable for ASCT treatment

Exclusion Criteria:

• Patients with contraindications to ASCT treatment

Related Conditions & MeSH terms

• Multiple Myeloma
• Myeloma, Multiple
• Neoplasms, Plasma Cell
• PET-CT

Locations

Country	Name	City	State
Norway	Oslo University Hosptal	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparing of image findings at PET		1 year